Get the Stockscreener App
4.1712
1.29%
-0.1588
Sonnet Biotherapeutics Holdings Inc stock is traded at $4.1712, with a volume of 11,823.
It is down -1.29% in the last 24 hours and down -17.01% over the past month.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$4.33
Open:
$4.22
24h Volume:
11,823
Relative Volume:
0.40
Market Cap:
$2.93M
Revenue:
$129.20K
Net Income/Loss:
$-14.46M
P/E Ratio:
-0.0645
EPS:
-64.68
Net Cash Flow:
$-18.52M
1W Performance:
-5.23%
1M Performance:
-17.01%
6M Performance:
-71.28%
1Y Performance:
-58.59%
1-Day Range:
$4.17
$4.39
1-Week Range:
$4.00
$4.61
52-Week Range:
$4.00
$18.72
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Name
Sonnet Biotherapeutics Holdings Inc
Sector
Industry
Phone
609-375-2227
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
Sonnet stock tumbles 22% in wake of proposed offering filing - MSN
(SONN) On The My Stocks Page - Stock Traders Daily
When (SONN) Moves Investors should Listen - Stock Traders Daily
Sonnet BioTherapeutics (SONN) Stock Surges After Regaining Nasdaq Compliance - Stocks Telegraph
Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance - TipRanks
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq - GlobeNewswire
SONN (Sonnet BioTherapeutics Holdings) Capex-to-Operating-C - GuruFocus.com
Sonnet BioTherapeutics meets Nasdaq listing requirements - Investing.com
Sonnet BioTherapeutics Enters into Licensing Agreement with Alkem Laboratories for DPN in India - Chemical Industry Digest
Alkem Labs inks pact with Sonnet BioTherapeutics to develop, commercialise drug candidate for diabetic... - Medical Dialogues
Alkem Labs enters into licensing agreement with Sonnet BioTherapeutics for its diabetic peripheral neuropathy drug in India - The Financial Express
Alkem Labs partners with Sonnet BioTherapeutics to develop drug candidate for diabetic peripheral neuropathy in India - BSI bureau
Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics - Equity Bulls
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment - Yahoo Finance
Alkem inks licensing pact with Sonnet BioTherapeutics for drug to treat diabetic neuropathy - Upstox
Alkem Licenses Drug for Diabetic Neuropathy in India - Rediffmail
Alkem and Sonnet BioTherapeutics Team Up for Diabetic Neuropathy Treatment - Devdiscourse
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India - The Manila Times
Sonnet BioTherapeutics, Alkem enter licensing agreement for SON-080 - TipRanks
SONN stock touches 52-week low at $4.8 amid market challenges By Investing.com - Investing.com South Africa
SONN stock touches 52-week low at $4.8 amid market challenges - Investing.com India
Sonnet BioTherapeutics receives funding through NJEDA, Australia tax programs - TipRanks
Sonnet BioTherapeutics secures tax credit approval By Investing.com - Investing.com Australia
Sonnet BioTherapeutics secures tax credit approval - Investing.com India
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs - ForexTV.com
Sonnet BioTherapeutics to Receive Non-Dilutive Funding - GlobeNewswire
Sonnet BioTherapeutics launches CEO Corner platform - Investing.com
Sonnet BioTherapeutics enacts reverse stock split By Investing.com - Investing.com Australia
Sonnet BioTherapeutics enacts reverse stock split - Investing.com India
Sonnet BioTherapeutics announces launch of CEO Corner platform - TipRanks
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform - GlobeNewswire
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - Benzinga
Sonnet BioTherapeutics enacts 1-for-8 reverse stock split By Investing.com - Investing.com South Africa
Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today - Benzinga
Sonnet BioTherapeutics enacts 1-for-8 reverse stock split - Investing.com India
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split - citybiz
Sonnet BioTherapeutics to execute 1-for-8 reverse stock split - MSN
Financial Contrast: Telomir Pharmaceuticals (NASDAQ:TELO) & Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics Completes Enrollment in Phase 1 - GlobeNewswire
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors - StockTitan
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics shareholders approve key proposals - Investing.com
Sonnet BioTherapeutics shareholders approve key proposals By Investing.com - Investing.com Canada
Sonnet BioTherapeutics to Present at Investor Series - TipRanks
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):